Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Simulations Plus Inc (NQ: SLP ) 36.61 -0.44 (-1.19%) Streaming Delayed Price Updated: 4:00 PM EDT, Aug 27, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Simulations Plus Inc < Previous 1 2 3 4 5 6 7 Next > Researchers Use the Simulations Plus DILIsym® Platform to Predict Safety of Combined CBD and VPA Treatment August 15, 2023 From Simulations Plus, Inc. Via Business Wire Simulations Plus Releases ADMET Predictor® 11 July 13, 2023 From Simulations Plus, Inc. Via Business Wire Recap: Simulations Plus Q3 Earnings July 06, 2023 Via Benzinga Simulations Plus's Earnings: A Preview July 05, 2023 Via Benzinga Preview: Simulations Plus's Earnings April 04, 2023 Via Benzinga Simulations An Attractive Vehicle For Investors Seeking Exposure To Biotech Innovation Themes, Analyst Says July 07, 2023 Oppenheimer analyst Francois Brisebois reiterated an Outperform rating on Simulations Plus, Inc. (NASDAQ: SLP) with a Via Benzinga Costco, AZZ And 3 Stocks To Watch Heading Into Friday July 07, 2023 With U.S. stock futures trading slightly lower this morning on Friday, some of the stocks that may grab investor focus today are as follows: Via Benzinga Simulations Plus Reports Third Quarter Fiscal 2023 Financial Results July 06, 2023 From Simulations Plus, Inc. Via Business Wire Simulations Plus Announces Third Quarter Fiscal Year 2023 Earnings and Conference Call Date June 21, 2023 From Simulations Plus, Inc. Via Business Wire Simulations Plus Is High-Growth Investment Opportunity In The Wake Of Immunetrics Acquisition: Analyst June 21, 2023 Oppenheimer analyst Francois Brisebois reiterated an Outperform rating on the shares of Simulations Plus, Inc. (NASDAQ: SLP), Via Benzinga Simulations Plus Acquires Immunetrics to Expand its Immunology and Oncology Drug Development Capabilities June 20, 2023 From Simulations Plus, Inc. Via Business Wire 7 Stocks Under $50 to Buy (and Never Sell) May 29, 2023 Although you usually get what you pay for, these best affordable stocks to invest in punch above their weight class. Via InvestorPlace Simulations Plus Launches New Integrated Pulmonary Software and Services Package to Streamline Drug Development and Improve Patient Outcomes May 10, 2023 From Simulations Plus, Inc. Via Business Wire Benzinga's Top Ratings Upgrades, Downgrades For May 9, 2023 May 09, 2023 Via Benzinga Roblox And 3 Other Stocks Insiders Are Selling April 28, 2023 The Nasdaq Composite closed sharply higher on Thursday. Investors, meanwhile, focused on some notable insider trades. Via Benzinga Simulations Plus Receives U.S. FDA Renewal for DILIsym Software Licenses April 18, 2023 From Simulations Plus, Inc. Via Business Wire Simulations Plus Reports Second Quarter Fiscal 2023 Financial Results April 05, 2023 From Simulations Plus, Inc. Via Business Wire MIDD+ 2023 Panelists Discuss How to Increase Gender Equity for Women in Science March 30, 2023 From Simulations Plus, Inc. Via Business Wire Simulations Plus Sets Date for Second Quarter Fiscal Year 2023 Earnings Release and Conference Call March 21, 2023 From Simulations Plus, Inc. Via Business Wire Simulations Plus to Present at Sidoti March Small-Cap Conference March 16, 2023 From Simulations Plus, Inc. Via Business Wire Simulations Plus Enters New Strategic Collaboration to Discover Anticancer Therapies Through Its AI-Driven Drug Design Technology March 28, 2023 From Simulations Plus, Inc. Via Business Wire Simulations Plus Enters Partnership to Apply AI/ML Technologies to Design Novel Compounds March 15, 2023 From Simulations Plus, Inc. Via Business Wire Lixoft Adds New Data Formatting and Reporting Modules to MonolixSuite™ in Version 2023R1 March 09, 2023 From Simulations Plus, Inc. Via Business Wire Simulations Plus to Present at Oppenheimer 33rd Annual Healthcare Conference March 07, 2023 From Simulations Plus, Inc. Via Business Wire Simulations Plus to Present at Raymond James 44th Annual Institutional Investors Conference February 28, 2023 From Simulations Plus, Inc. Via Business Wire Simulations Plus and Global Agrochemicals Leader to Collaborate on Machine Learning Models February 16, 2023 From Simulations Plus, Inc. Via Business Wire Simulations Plus Releases Redesigned NAFLDsym® QSP Software Tool February 09, 2023 From Simulations Plus, Inc. Via Business Wire Simulations Plus Releases DILIsym X (DSX) Beta with Redesigned Software Infrastructure January 12, 2023 From Simulations Plus, Inc. Via Business Wire Simulations Plus Executes $20 Million Accelerated Share Repurchase Agreement January 11, 2023 From Simulations Plus, Inc. Via Business Wire Why ABVC BioPharma Shares Are Trading Higher By 129%? Here Are Other Stocks Moving In Thursday's Mid-Day Session January 05, 2023 Gainers Bellerophon Therapeutics, Inc. (NASDAQ: BLPH) shares surged 179.3% to $2.4585 after the company announced that it has entered into a license agreement for the development and commercialization... Via Benzinga < Previous 1 2 3 4 5 6 7 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.